Episode 243: ASCO 2023 - TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide

Karim Fizazi, MD, PhD, joins us at ASCO 2023 to discuss the results of the phase 3 TALAPRO-2 study results of talazoparib plus enzalutamide for mCRPC.
Dr. Fizazi is a medical oncologist at Institute Gustave Roussy specializing in the management of prostate cancer, as well as a professor of oncology at the University of Paris-Saclay.